FDA Approves Sunharbo to Cut Recurrent Stroke Risk
A new FDA-approved stroke-prevention pill cut ischemic stroke risk by 26% in a 12,327-person trial, but its use is limited to specific patients.
By shahzad
7 min read2 readers
In this story
Key takeaways
The FDA approved Sunharbo (asundexian) on November 9, 2026, to reduce the risk of another stroke in certain adults after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.
In the 12,327-person Phase 3 OCEANIC-STROKE trial, ischemic strokes occurred in 6.2% of participants taking asundexian and 8.4% taking placebo, a 26% relative reduction.
The medicine must be combined with antiplatelet therapy; patients should not change existing stroke-prevention medicines without their care team.
The U.S. Food and Drug Administration approved Sunharbo (asundexian) on November 9, 2026, as a once-daily treatment to lower the risk of another ischemic stroke in certain adults who recently had a non-cardioembolic stroke or high-risk TIA. The approval adds a new type of clotting medicine to secondary stroke prevention, but it is not intended for every stroke survivor and carries important bleeding and drug-interaction warnings.
"A pharmacy professional stands beside shelves of medicine. Photo by National Cancer Institute on Unsplash; illustrative stock photo, not a Sunharbo product image."
What did the FDA approve?
The FDA approved Sunharbo, the brand name for asundexian, in 50-milligram tablets. It is the first factor XIa (FXIa) inhibitor approved in the United States. Factor XIa is an enzyme involved in the blood-clotting process; inhibiting it is a different approach from several established antiplatelet and anticoagulant treatments.
The approved use is specific: Sunharbo is indicated with antiplatelet therapy for adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. A non-cardioembolic stroke is caused by a clot that did not originate in the heart. A TIA, sometimes called a mini-stroke, causes temporary stroke-like symptoms and is a warning that requires urgent medical assessment.
The FDA's November 9 approval announcement says the recommended dose is 50 mg once daily, in combination with antiplatelet therapy. Sunharbo is not approved to prevent strokes caused by atrial fibrillation.
How much did Sunharbo reduce stroke risk in the trial?
The approval was supported by OCEANIC-STROKE, a multicenter, randomized, double-blind Phase 3 trial involving 12,327 adults. Researchers assigned 6,162 participants to asundexian and 6,165 to placebo, with both groups also receiving antiplatelet therapy.
The FDA reported that ischemic stroke occurred in 6.2% of people taking asundexian and 8.4% of those taking placebo. That is a 26% relative reduction in the risk of ischemic stroke over a median treatment period of 14.2 months.
The distinction between relative and absolute reduction matters. The difference between the two trial percentages was 2.2 percentage points; the 26% figure describes the relative reduction compared with the placebo group. It does not mean that 26 out of every 100 patients will avoid a stroke.
The New England Journal of Medicine trial report, published April 16, 2026, also reported fewer ischemic strokes in the asundexian group. It found major bleeding rates of 1.9% with asundexian and 1.7% with placebo during median follow-up of 19 months. The study was funded by Bayer, the drug's manufacturer.
"A laboratory researcher works with a microscope. Photo by Thirdman on Pexels; illustrative stock photo, not an image from the OCEANIC-STROKE trial."
What are the risks and who should be cautious?
The FDA says the overall rate of major bleeding was similar between the Sunharbo and placebo groups. However, its review identified higher major-bleeding rates among patients older than 75 and during the first 90 days of treatment. Gastrointestinal bleeding was also more common with Sunharbo, and diarrhea was the most frequently reported adverse reaction occurring in at least 3% of treated patients.
The FDA also says Sunharbo is not recommended for people with moderate or severe liver impairment. Taking it with certain medicines that strongly induce both P-glycoprotein and CYP3A4, including carbamazepine, is not recommended because those drugs may reduce Sunharbo's effectiveness.
The agency advises withholding Sunharbo for at least 24 hours before elective surgery or invasive procedures and for at least 24 hours after thrombolysis for an acute ischemic stroke. These are prescribing precautions for clinicians to manage; patients should not stop or adjust a prescribed medicine on their own.
For broader context on recent FDA medication-label decisions, see Big Zero's coverage of the new GLP-1 eye-risk warnings. Big Zero has also explained why patients should discuss medication changes with clinicians in its report on the statin-discontinuation trial.
What should stroke and TIA survivors do now?
Sunharbo's approval does not mean every person who has had a stroke or TIA should take it. The FDA indication is limited to adults with a recent non-cardioembolic ischemic stroke or high-risk TIA, and the treatment is used alongside antiplatelet therapy.
If you or a family member is recovering from one of these events, practical next steps are:
Keep taking prescribed antiplatelet, anticoagulant, blood-pressure or cholesterol medicines unless the treating clinician changes the plan.
Ask the stroke specialist whether the original event was non-cardioembolic and whether the patient matches the FDA-approved population.
Review all prescription medicines, over-the-counter drugs and supplements with the clinician or pharmacist to check for interactions and bleeding risks.
Ask how age, liver health, prior bleeding, planned procedures and the timing of the stroke or TIA affect the treatment decision.
Bayer says it expects Sunharbo shipments to begin in mid-to-late November 2026, with hospital and pharmacy ordering to follow shortly afterward. The company has not provided a universal patient out-of-pocket price in the FDA announcement, so coverage and individual costs should be checked with a pharmacy and insurer.
What is still unknown?
The FDA approval establishes the permitted use, but it does not answer every practical question for patients. Pharmacy availability will depend on the rollout, while insurance coverage and out-of-pocket costs may vary by plan.
Longer-term use outside the trial's follow-up, effectiveness in groups not represented by the approved indication, and how clinicians will position the medicine alongside existing prevention strategies will require continued clinical experience and further evidence. The FDA approval does not extend to stroke prevention in people with atrial fibrillation.
FAQ
Is Sunharbo approved for all stroke survivors?
No. The FDA approved it for adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA, in combination with antiplatelet therapy. It is not approved for stroke prevention in people with atrial fibrillation.
How much does Sunharbo reduce the risk of another stroke?
In OCEANIC-STROKE, ischemic stroke occurred in 6.2% of participants taking asundexian and 8.4% taking placebo. The FDA described this as a 26% relative risk reduction over a median treatment period of 14.2 months.
Does Sunharbo replace aspirin or other antiplatelet medicines?
No. The FDA indication specifies that Sunharbo is used in combination with antiplatelet therapy. A clinician must decide which medicines are appropriate for an individual patient.
What is the main safety concern?
Bleeding is a key concern. The FDA reported higher major-bleeding rates in patients older than 75 and during the first 90 days of treatment, as well as more gastrointestinal bleeding with Sunharbo.
When will Sunharbo be available in U.S. pharmacies?
Bayer expects shipments to begin in mid-to-late November 2026, followed by availability for hospitals and pharmacies to order. Actual availability and insurance coverage may vary.
Bottom line
Sunharbo gives eligible patients a new FDA-approved option to reduce recurrent ischemic stroke risk, backed by a large Phase 3 trial. Its use is specific and bleeding risks matter, so the next step for a potentially eligible patient is to discuss the trial results, medication list and personal risk factors with a stroke specialist—not to change treatment independently.
